This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study on the Effects of Soy Protein on Blood Lipids in Men and Women With Mild to Moderate Hypercholesterolemia (PRV-08009)

This study has been completed.
Information provided by (Responsible Party):
Solae, LLC Identifier:
First received: July 21, 2009
Last updated: June 6, 2012
Last verified: June 2012
The objectives of the trial are to determine whether a non-commercial soy protein product, consumed as part of a low-saturated fat diet, reduces low-density lipoprotein cholesterol (LDL-C) concentrations in men and women with mild to moderate hypercholesterolemia, and affects other aspects related biomarkers.

Condition Intervention
Hypercholesterolemia Dietary Supplement: Soy protein; 25 grams/day Dietary Supplement: Control protein

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Randomized, Controlled Parallel Study to Evaluate the Effects of a Non-Commercial Soy Protein Product on Fecal Bile Acids and Blood Lipids in Men and Women With Mild to Moderate Hypercholesterolemia

Resource links provided by NLM:

Further study details as provided by Solae, LLC:

Primary Outcome Measures:
  • The difference between treatment groups in the percent change from baseline to the end of treatment in LDL-C [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Changes in other lipid levels and other related biomarkers [ Time Frame: 4 weeks ]

Enrollment: 60
Study Start Date: April 2009
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Soy protein Dietary Supplement: Soy protein; 25 grams/day
Soy protein
Placebo Comparator: Milk protein Dietary Supplement: Control protein
Milk protein


Ages Eligible for Study:   18 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female
  • 18-79 years of age
  • Fasting LDL-Cholesterol level borderline to high range taking no cholesterol lowering medications
  • otherwise judged to be in good health, willing to maintain a stable body weight and follow the TLC diet throughout the trial.

Exclusion Criteria:

  • CHD or CHD risk equivalent
  • Pregnancy
  • Food allergy or sensitivity to soy or milk protein
  • Certain muscle, liver, kidney, lung or gastrointestinal conditions and medications
  • Poorly controlled hypertension
  • Cancer treated within prior 2 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00945737

United States, Illinois
Provident Clinical Research
Addison, Illinois, United States, 60101
United States, Indiana
Provident Clinical Research
Bloomington, Indiana, United States, 47403
Sponsors and Collaborators
Solae, LLC
Principal Investigator: Matthew Reeves, DO Provident Clinical Research
Principal Investigator: Mano Patri, MD Provident Clinical Research, Addison, IL
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Solae, LLC Identifier: NCT00945737     History of Changes
Other Study ID Numbers: PRV-08009
Study First Received: July 21, 2009
Last Updated: June 6, 2012

Keywords provided by Solae, LLC:

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on August 18, 2017